Promedior Appoints William Hodder as Vice President of Business Development
Lexington, Mass., January 8, 2014 — Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that biopharmaceutical industry veteran William Hodder has joined the company as Vice President of Business Development. Mr. Hodder will be responsible for leading the Promedior's business development activities as its lead drug candidates targeting fibrosis continue to advance through clinical development for serious and life threatening fibrotic diseases, including myelofibrosis and idiopathic pulmonary fibrosis (IPF).
"We are pleased to welcome William Hodder to Promedior's senior management team," said Suzanne L. Bruhn, PhD, President and Chief Executive Officer of Promedior. "Mr. Hodder's strong experience in the biotechnology industry and specifically within the field of fibrotic diseases is a perfect fit for our needs as we continue to deepen and broaden the clinical data from our ongoing programs and consider partnerships for the next stage of our growth."
Mr. Hodder brings to Promedior more than 25 years of pharmaceutical and biotechnology industry experience. Prior to joining Promedior, Mr. Hodder was founder and CEO of Trenovus, Inc. a start-up biotechnology company focused on developing novel inhibitors of heterotopic ossification. Prior to Trenovus, Mr. Hodder was Vice President, Business Development of FibroGen, Inc., where he was responsible for all licensing and M&A activity. Significantly, Mr. Hodder led FibroGen in the historic out-licensing of HIF prolyl hydroxylase inhibitors for anemia indications to Astellas for the European, South Africa and Middle East territories. Prior to joining FibroGen, he served as Director of Business Development and Marketing at drug delivery company Aradigm and held sales, marketing, and product development positions at Penederm, Ciba Geigy, Bristol-Myers Squibb Company, and Marion Laboratories. Mr. Hodder completed his undergraduate studies at Oakland University with a B.S. in biology and holds an M.B.A. from the University of Chicago Booth School of Business.
"I am excited to join Promedior and look forward to forging the key business alliances that will build on the strength of the company's clinical data to help to drive the company's growth," said William Hodder, Vice President of Business Development for Promedior. "It is a privilege to work with a group so committed to delivering new therapeutic options for fibrotic diseases to physicians and patients."
Promedior is a clinical stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. Fibrosis is a harmful process that occurs in many diseases, when normal healthy tissue is replaced with excessive scar tissue, compromising function and ultimately leading to organ failure. Promedior's proprietary platform is based upon Pentraxin-2, an endogenous human protein that is specifically active at the site of tissue damage and works as an agonist, preventing and potentially reversing fibrosis.
Promedior has successfully advanced its lead therapeutic candidate in human clinical trials, and is initially focused on rare fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and myelofibrosis. Promedior is backed by leading global healthcare venture investors, has a significant intellectual property estate relating to the discoveries and applications of Pentraxin-2 therapeutics and is led by an experienced management team. For additional information about Promedior, please visit www.promedior.com.